ASP Isotopes (NASDAQ:ASPI) Trading Down 5.1% on Insider Selling

Key Points

• Insider selling: Shares dropped about 5.1% after COO Robert Ainscow sold 25,000 shares at $4.51 (≈$112,750), trimming his stake by 1.63%; the stock hit $4.79 on below-average volume.
• Earnings miss but revenue beat: ASP reported Q EPS of ($0.84) versus ($0.14) expected, with extreme negative net margin (−734%) and ROE (−308%), while revenue came in at $33.32M versus $2.03M expected.
• Mixed analyst and institutional signals: Two Buys and one Sell translate to a consensus "Hold" with a $13.00 price target, even as major institutions (Alyeska, UBS, Vanguard, Marshall Wace) significantly increased their stakes.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report)'s share price fell 5.1% during trading on Tuesday following insider selling activity. The stock traded as low as $4.79 and last traded at $4.8040. 2,717,844 shares were traded during mid-day trading, a decline of 48% from the average session volume of 5,234,062 shares. The stock had previously closed at $5.06.

Specifically, COO Robert Ainscow sold 25,000 shares of the business's stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $4.51, for a total value of $112,750.00. Following the completion of the transaction, the chief operating officer owned 1,512,817 shares of the company's stock, valued at $6,822,804.67. The trade was a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ASPI. Weiss Ratings reissued a "sell (d-)" rating on shares of ASP Isotopes in a research report on Friday, March 27th. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 target price on shares of ASP Isotopes in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $13.00.

ASP Isotopes Trading Down 5.6%

The business's fifty day moving average is $5.10 and its 200-day moving average is $6.83. The stock has a market capitalization of $529.26 million, a PE ratio of -2.23 and a beta of 3.59. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its earnings results on Friday, April 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.70). ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 307.82%. The company had revenue of $33.32 million during the quarter, compared to analysts' expectations of $2.03 million. As a group, analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On ASP Isotopes

Several institutional investors have recently bought and sold shares of ASPI. Alyeska Investment Group L.P. grew its stake in ASP Isotopes by 73.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company's stock worth $26,191,000 after buying an additional 2,072,851 shares during the period. UBS Group AG grew its stake in ASP Isotopes by 150.3% during the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company's stock worth $12,875,000 after buying an additional 1,445,165 shares during the period. Marshall Wace LLP grew its stake in ASP Isotopes by 3,669.1% during the third quarter. Marshall Wace LLP now owns 1,279,121 shares of the company's stock worth $12,305,000 after buying an additional 1,245,184 shares during the period. Vanguard Group Inc. grew its stake in ASP Isotopes by 37.9% during the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company's stock worth $43,451,000 after buying an additional 1,241,024 shares during the period. Finally, Rovida Investment Management Ltd grew its stake in ASP Isotopes by 45.5% during the third quarter. Rovida Investment Management Ltd now owns 3,200,000 shares of the company's stock worth $30,688,000 after buying an additional 1,000,000 shares during the period. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.